📊 PULM Key Takeaways
Is Pulmatrix, Inc. (PULM) a Good Investment?
Pulmatrix is a pre-revenue biotech company with minimal revenue generation ($53K) despite near-term cash burn of $5.8M quarterly (negative free cash flow). With only $4.1M in cash on hand, the company has less than one year of operational runway at current burn rates, creating existential risk absent significant external financing or transformative clinical/commercial milestones.
Why Buy Pulmatrix, Inc. Stock? PULM Key Strengths
- Zero long-term debt with clean balance sheet
- Strong liquidity position with 12.55x current ratio
- Net loss improvement of 46% YoY indicates some operational progress
PULM Stock Risks: Pulmatrix, Inc. Investment Risks
- Unsustainable quarterly cash burn of -$5.8M against $4.1M total cash reserves (sub-12 month runway)
- Operating margin of -9752% with minimal revenue generation signals no clear path to profitability
- No insider buying activity in 90 days; typical of distressed biotech situations
- Revenue base of $53K is immaterial and does not support operating expenses
Key Metrics to Watch
- Cash burn rate and duration of cash runway before financing need
- Revenue growth trajectory and evidence of commercial traction or partnering
- Clinical trial progress and pipeline advancement as potential catalysts
Pulmatrix, Inc. (PULM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.55x current ratio provides a solid financial cushion.
PULM Profit Margin, ROE & Profitability Analysis
PULM vs Healthcare Sector: How Pulmatrix, Inc. Compares
How Pulmatrix, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pulmatrix, Inc. Stock Overvalued? PULM Valuation Analysis 2026
Based on fundamental analysis, Pulmatrix, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pulmatrix, Inc. Balance Sheet: PULM Debt, Cash & Liquidity
PULM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pulmatrix, Inc.'s revenue has declined by 38% over the 5-year period, indicating business contraction. The most recent EPS of $-2.62 indicates the company is currently unprofitable.
PULM Revenue Growth, EPS Growth & YoY Performance
PULM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $366.0K | $825.0K | $-0.24 |
| Q2 2025 | $1.6M | $825.0K | $-0.42 |
| Q1 2025 | $5.9M | $825.0K | $0.23 |
| Q3 2024 | $366.0K | $825.0K | $-0.71 |
| Q2 2024 | $1.6M | $825.0K | $-1.04 |
| Q1 2024 | $1.5M | $825.0K | $0.23 |
| Q3 2023 | $1.8M | -$3.8M | $-1.03 |
| Q2 2023 | $1.3M | -$3.8M | $-1.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pulmatrix, Inc. Dividends, Buybacks & Capital Allocation
PULM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pulmatrix, Inc. (CIK: 0001574235)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PULM
What is the AI rating for PULM?
Pulmatrix, Inc. (PULM) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PULM's key strengths?
Claude: Zero long-term debt with clean balance sheet. Strong liquidity position with 12.55x current ratio.
What are the risks of investing in PULM?
Claude: Unsustainable quarterly cash burn of -$5.8M against $4.1M total cash reserves (sub-12 month runway). Operating margin of -9752% with minimal revenue generation signals no clear path to profitability.
What is PULM's revenue and growth?
Pulmatrix, Inc. reported revenue of $53.0K.
Does PULM pay dividends?
Pulmatrix, Inc. does not currently pay dividends.
Where can I find PULM SEC filings?
Official SEC filings for Pulmatrix, Inc. (CIK: 0001574235) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PULM's EPS?
Pulmatrix, Inc. has a diluted EPS of $-1.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PULM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pulmatrix, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PULM stock overvalued or undervalued?
Valuation metrics for PULM: ROE of -135.5% (sector avg: 15%), net margin of -9,739.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PULM stock in 2026?
Our dual AI analysis gives Pulmatrix, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PULM's free cash flow?
Pulmatrix, Inc.'s operating cash flow is $-5.4M, with capital expenditures of $398.0K. FCF margin is -11,001.9%.
How does PULM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,739.6% (avg: 12%), ROE -135.5% (avg: 15%), current ratio 12.55 (avg: 2).